MetastaticBreastCancer Archives

Dr. Jiayu Wang: Revisiting International Conferences with Promising Efficacy Data – Domestic Innovative CDK4/6 Inhibitor Birociclib as a New Choice for HR+/HER2-MBC Treatment

By Mourabit Halima 2023.12.07

Editor's Note: During the 2023 European Society for Medical Oncology (ESMO) Annual Meeting, a Phase II multi-center clinical trial's results, led by Academician Xu Binghe and his team from the…

ESMO 2023 | SKB264 (TROP2-ADC) Shows Promise in the Treatment of HR+/HER2- Metastatic Breast Cancer, Advancing in Multiple Cancer Types

By Lisa Cui 2023.12.07

TROP2 (Trophoblast Cell-Surface Antigen 2) is highly expressed in various solid tumors, making it a hot target in the field of oncology. The development of antibody-drug conjugates (ADCs) targeting this…

2023 ESMO Congress Reveals YOUNGBC-21 Study Results

By Mourabit Halima 2023.12.07

Editor's note: HER2-positive metastatic breast cancer (HER2+ MBC) has seen the emergence of several new drugs, but the combination of Pyrotinib with dual targeting therapy remains the preferred first-line option.…